Hepatitis Monthly

Published by: Kowsar

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

Seyed Moayed Alavian 1 , 2 , * , Behzad Hajarizadeh 3 , Kamran Bagheri Lankarani 4 , Heidar Sharafi 1 , 2 , Nasser Ebrahimi Daryani 5 , Shahin Merat 6 , Minoo Mohraz 7 , Masoud Mardani 8 , Mohamad Reza Fattahi 9 , Hossein Poustchi 6 , Mehri Nikbin 2 , Mahmood Nabavi 10 , Peyman Adibi 11 , Masood Ziaee 12 , Bita Behnava 1 , 2 , Mohammad Saeid Rezaee-Zavareh 1 , 2 , 13 , Massimo Colombo 14 , Hatef Massoumi 15 , Abdul Rahman Bizri 16 , Bijan Eghtesad 17 , Majid Amiri 18 , Ali Namvar 19 , Khashayar Hesamizadeh 1 , 2 and Reza Malekzadeh 6
Authors Information
1 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 Middle East Liver Diseases (MELD) Center, Tehran, IR Iran
3 Viral Hepatitis Clinical Research Program, The Kirby Institute, The University of New South Wales (UNSW Australia), Sydney, Australia
4 Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
5 Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, IR Iran
6 Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, IR Iran
7 Iranian Research Center for HIV/AIDS (IRCHA), Tehran University of Medical Sciences, Tehran, IR Iran
8 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
9 Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
10 Department of Infectious Diseases and Tropical Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
11 Department of Gastroenterology and Hepatology, Isfahan University of Medical Sciences, Isfahan, IR Iran
12 Hepatitis Research Center, Birjand University of Medical Sciences, Birjand, IR Iran
13 Student’s Research Committee, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
14 Department of Medicine, Gastroenterology Division 1, AM and A Migliavacca Center for the Study of Liver Disease, Ca’ Granda Ospedale Maggiore Policlinico, University of Milan, Italy
15 New York Associates in Gastroenterology, Bronx, New York, USA
16 Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
17 Cleveland Clinic, Cleveland, OH, USA
18 Gastroenterology and Hepatology Department, Gouin Hospital, Clichy, France
19 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, IR Iran
Article information
  • Hepatitis Monthly: August 01, 2016, 16 (8); e40959
  • Published Online: August 13, 2016
  • Article Type: Review Article
  • Received: July 31, 2016
  • Accepted: July 31, 2016
  • DOI: 10.5812/hepatmon.guideline

To Cite: Alavian S M, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline, Hepat Mon. 2016 ; 16(8):e40959. doi: 10.5812/hepatmon.guideline.

Copyright © 2016, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
  • 1. Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, Lai ST, et al. Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol. 2001; 65(3): 505-9[PubMed]
  • 2. Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010; 14(1): 1-21[DOI][PubMed]
  • 3. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17(2): 107-15[DOI][PubMed]
  • 4. Daw MA, Dau AA. Hepatitis C virus in Arab world: a state of concern. ScientificWorldJournal. 2012; 2012: 719494[DOI][PubMed]
  • 5. Alavian SM, Haghbin H. Relative Importance of Hepatitis B and C Viruses in Hepatocellular Carcinoma in EMRO Countries and the Middle East: A Systematic Review. Hepat Mon. 2016; 16(3): 35106[DOI][PubMed]
  • 6. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014; 61(1 Suppl)-57[DOI][PubMed]
  • 7. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 8. Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden. Hepat Mon.
  • 9. Miri S, Alavian SM. Increasing the HCV Prevalence in Ahvaz: Bells Ring. Jundishapur J Microbiol. 2012; 6(3): 309-10
  • 10. Alavian SM, Aalaei-Andabili SH. Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis. Hepat Mon. 2012; 12(4): 244-52[DOI][PubMed]
  • 11. Alavian SM, Tabatabaei SV, Lankarani KB. Epidemiology of HCV Infection among Thalassemia Patients in eastern Mediterranean Countries: a Quantitative Review of Literature. Iran Red Cres Med J. 2010; 12(4): 365-76
  • 12. Alavian SM. Hepatitis C virus infection: Epidemiology, risk factors and prevention strategies in public health in I.R. IRAN. . Gastroenterol Hepatol Bed Bench. 2010; 3(1): 5-14
  • 13. Alavian SM, Fallahian F. Epidemiology of Hepatitis C in Iran and the World. Shiraz E-Med J. 2009; 10(4): 162-72
  • 14. Sahli ZT, Bizri AR, Abu-Sittah GS. Microbiology and risk factors associated with war-related wound infections in the Middle East. Epidemiol Infect. 2016; : 1-10[DOI][PubMed]
  • 15. Rezaee-Zavareh MS, Einollahi B. Hepatitis B vaccination: needs a revision. Hepat Mon. 2014; 14(3): 17461[DOI][PubMed]
  • 16. Allison RD, Teleb N, Al Awaidy S, Ashmony H, Alexander JP, Patel MK. Hepatitis B control among children in the Eastern Mediterranean Region of the World Health Organization. Vaccine. 2016; 34(21): 2403-9[DOI][PubMed]
  • 17. Miri-Bonjar M, Khorram A, Ansari-Moghaddam A. The Necessity of Enhanced Harm Reduction Programs to Prevent Blood-Borne Infections Amongst Injection Drug Users. Health Scope. 2016; 5(1)
  • 18. Alavian SM. Control of Hepatitis C in Iran: Vision and Missions. Hepat Mon. 2007; 7(2): 57-558
  • 19. Alavian SM, Asl MA, Lankarani KB, Shahbabaie MA, Ahmadi AB, Kabir A. Hepatitis C Infection in the General Population of Iran: A Systematic Review. . Hepat month. 2009; 9(3): 211-23
  • 20. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014; 59(1): 318-27[DOI][PubMed]
  • 21. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012; 12(9): 6151[DOI][PubMed]
  • 22. Sharafi H, Alavian SM. IL28B polymorphism, Explanation for Different Responses to Therapy in Hepatitis C Patients. Hepat Mon. 2011; 11(12): 958-9[DOI][PubMed]
  • 23. Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new direct-acting antivirals. Expert Opin Drug Metab Toxicol. 2016; : 1-13[DOI][PubMed]
  • 24. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370(20): 1889-98[DOI][PubMed]
  • 25. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014; 370(16): 1483-93[DOI][PubMed]
  • 26. Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther. 2009; 30(6): 557-76[DOI][PubMed]
  • 27. Thompson AJ. Australian recommendations for the management of hepatitis C virus infection: a consensus statement. Med J Aust. 2016; 204(7): 268-72[PubMed]
  • 28. European Association for Study of L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2014; 60(2): 392-420[DOI][PubMed]
  • 29. Alavian SM, Lankarani KB, Aalaei-Andabili SH, Pouryasin A, Daryani NE, Toosi MN, et al. Treatment of Chronic Hepatitis C Infection: Update of the Recommendations from Scientific Leader's Meeting-28th July 2011-Tehran, IR Iran. Hepat Month. 2011; 11(9): 703-13[DOI]
  • 30. Alavian SM, Jabbari H, Ebrahimi Daryani N, Torabi nami M. Hepatitis c virus: The rising concerns and growing hopes, report from the hcv symposium, fourth tehran hepatitis congress, november 2011, tehran, iran. Hepatitis Monthly. 2012; 12(7): 423-9[DOI]
  • 31. Behnava B, Sharafi H, Keshvari M, Pouryasin A, Mehrnoush L, Salimi S, et al. The Role of Polymorphisms Near the IL28B Gene on Response to Peg-Interferon and Ribavirin in Thalassemic Patients With Hepatitis C. Hepat Mon. 2016; 16(1): 32703[DOI][PubMed]
  • 32. Pouresmaeeli M, Alavian SM, Keshvari M, Salimi S, Mehrnoush L. Efficacy and Tolerability of Peginterferon alpha-2a and Peginterferon alpha-2b in Iranian Patients With Chronic Hepatitis C. Hepat Mon. 2015; 15(9): 30780[DOI][PubMed]
  • 33. Ermis F, Senocak Tasci E. New treatment strategies for hepatitis C infection. World J Hepatol. 2015; 7(17): 2100-9[DOI][PubMed]
  • 34. Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, et al. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon. 2014; 14(10): 22215[DOI][PubMed]
  • 35. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016; 16(4): 37089[DOI][PubMed]
  • 36. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368(1): 34-44[DOI][PubMed]
  • 37. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20): 1878-87[DOI][PubMed]
  • 38. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, et al. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012; 57(1): 24-31[DOI][PubMed]
  • 39. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014; 370(20): 1879-88[DOI][PubMed]
  • 40. Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RJ, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015; 149(3): 649-59[DOI][PubMed]
  • 41. Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis. 2015; 15(4): 397-404[DOI][PubMed]
  • 42. Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourliere M. The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study. Liver Int. 2016; 36(1): 42-8[DOI][PubMed]
  • 43. Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, et al. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. Lancet Infect Dis. 2015; 15(1): 27-35[DOI][PubMed]
  • 44. McConachie SM, Wilhelm SM, Kale-Pradhan PB. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol 2016; 9(2): 287-302[DOI][PubMed]
  • 45. Maan R. Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease. van der Meer AJ. 2016; 5[DOI][PubMed]
  • 46. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016; 63(5): 1493-505[DOI][PubMed]
  • 47. Wyles DL, Ruane PJ, Sulkowski MS, Dieterich D, Luetkemeyer A, Morgan TR, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015; 373(8): 714-25[DOI][PubMed]
  • 48. Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015; 61(4): 1127-35[DOI][PubMed]
  • 49. Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016; 63(5): 1430-41[DOI][PubMed]
  • 50. Manolakopoulos S, Zacharakis G, Zissis M, Giannakopoulos V. Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C. Ann Gastroenterol. 2016; 29(3): 282-96[DOI][PubMed]
  • 51. Aasld Idsa Hcv Guidance Panel . Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015; 62(3): 932-54[DOI][PubMed]
  • 52. Gane E, Ben Ari Z, Mollison L, Zuckerman E, Bruck R, Baruch Y, et al. Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection. J Viral Hepat. 2016; [DOI][PubMed]
  • 53. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Jacobson I, Agarwal K, et al. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial. J Hepatol. 2016; 65(1): 33-9[DOI][PubMed]
  • 54. Foster GR, Afdhal N, Roberts SK, Brau N, Gane EJ, Pianko S, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med. 2015; 373(27): 2608-17[DOI][PubMed]
  • 55. Curry MP, O'Leary JG, Bzowej N, Muir AJ, Korenblat KM, Fenkel JM, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med. 2015; 373(27): 2618-28[DOI][PubMed]
  • 56. Feld JJ, Jacobson IM, Hezode C, Asselah T, Ruane PJ, Gruener N, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med. 2015; 373(27): 2599-607[DOI][PubMed]
  • 57. Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med. 2015; 163(11): 818-26[DOI][PubMed]
  • 58. Basnayake SK, Easterbrook PJ. Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature. J Viral Hepat. 2016; 23(7): 545-59[DOI][PubMed]
  • 59. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010; 138(2): 513-21[DOI][PubMed]
  • 60. Ebrahimi ND, Alavian SM, Somi MH, Torabi-Nami M. Hepatitis c and why the treatment is needed now? The summary report from the cross-border symposium of the 5th tehran hepatitis congress may 2013. Hepat Month. 2013; 13(11)[DOI]
  • 61. Backus LI, Belperio PS, Shahoumian TA, Loomis TP, Mole LA. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther. 2015; 42(5): 559-73[DOI][PubMed]
  • 62. Lawitz E, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 369(7): 678-9[DOI][PubMed]
  • 63. Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381(9883): 2100-7[DOI][PubMed]
  • 64. Lawitz E, Lalezari JP, Hassanein T, Kowdley KV, Poordad FF, Sheikh AM, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis. 2013; 13(5): 401-8[DOI][PubMed]
  • 65. European Association for Study of L. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015; 63(1): 199-236[DOI][PubMed]
  • 66. Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, et al. Efficacy of sofosbuvir plus ribavirin in veterans with hepatitis c virus genotype 2 infection, compensated cirrhosis, and multiple comorbidities. Clin Gastroenterol Hepatol. 2016;
  • 67. Welzel TM, Dultz G, Zeuzem S. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors. Journal of hepatology 2014; 61(1 Suppl)[DOI][PubMed]
  • 68. Ampuero J, Romero-Gomez M. Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3. Gastroenterol Clin North Am. 2015; 44(4): 845-57[DOI][PubMed]
  • 69. Foster GR, Pianko S, Brown A, Forton D, Nahass RG, George J, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015; 149(6): 1462-70[DOI][PubMed]
  • 70. LP05: Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: interim analysis of a French multicenter compassionate use program. The International Liver Congress™ 2015–50th Annual meeting of the European Association for the Study of the Liver.
  • 71. Ampuero J, Reddy KR, Romero-Gomez M. Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options. World J Gastroenterol. 2016; 22(22): 5285-92[DOI][PubMed]
  • 72. Abergel A, Metivier S, Samuel D, Jiang D, Kersey K, Pang PS, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016; [DOI][PubMed]
  • 73. Hezode C, De Ledinghen V, Fontaine H, Zoulim F, Lebray P, Boyer N, et al. LP05 : Daclatasvir plus sofosbuvir with or without ribavirin in patients with HCV genotype 3 infection: Interim analysis of a french multicenter compassionate use program. J Hepatol. 2015; 62-6[DOI]
  • 74. Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, et al. Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis. Lancet Infect Dis. 2016; 16(7): 797-808[DOI][PubMed]
  • 75. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33(4): 562-9[DOI][PubMed]
  • 76. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999; 30(4): 1054-8[DOI][PubMed]
  • 77. WHO guidelines approved by the guidelines review committee. . Guidelines for the Screening Care and Treatment of Persons with Chronic Hepatitis C Infection: Updated Version. 2009;
  • 78. Sogni P, Gilbert C, Lacombe K, Piroth L, Rosenthal E, Miailhes P, et al. All-oral Direct-acting Antiviral Regimens in HIV/Hepatitis C Virus-coinfected Patients With Cirrhosis Are Efficient and Safe: Real-life Results From the Prospective ANRS CO13-HEPAVIH Cohort. Clin Infect Dis. 2016; [DOI][PubMed]
  • 79. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl. 2008; 14 Suppl 2-44[DOI][PubMed]
  • 80. Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol. 2016; 8(1): 69-73[DOI][PubMed]
  • 81. Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT. Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation. Transpl Int. 2015; 28(8): 980-9[DOI][PubMed]
  • 82. Akamatsu N, Sugawara Y, Kokudo N, Eguchi S, Fujiwara T, Ohdan H, et al. Outcomes of living donor liver transplantation for hepatitis C virus-positive recipients in Japan: results of a nationwide survey. Transpl Int. 2014; 27(8): 767-74[DOI][PubMed]
  • 83. Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: phase 3 ALLY-1 study J Hepatol. 2015; 62
  • 84. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016; 16(6): 685-97[DOI][PubMed]
  • 85. Gutierrez JA, Carrion AF, Avalos D, O'Brien C, Martin P, Bhamidimarri KR, et al. Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients. Liver Transpl. 2015; 21(6): 823-30[DOI][PubMed]
  • 86. Tahan V, Almashhrawi A, Kahveci AM, Mutrux R, Ibdah JA. Name of Journal: World Journal of Hepatology ESPS Manuscript NO: 24721 Manuscript Type: Minireviews Extension for Community Health Outcomes-hepatitis C: Small steps carve big footprints in the allocation of scarce resources for hepatitis C virus treatment to remote developing areas.
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments